Scientific Affiliations
Harvard Medical School Brigham & Women's Hospital University Hospital Zürich Heidelberg University University of Cambridge University College London
Medical Outcomes Analytics

Publication-Grade Evidence from Big Data Registries.

ACP Data Lab helps pharmaceutical, medtech, and healthcare teams transform surgical and medical registry data into publication-grade evidence, sharper strategy, and decision-ready insight.

View Research ↓
🔒 De-identified Data 📋 IRB Compliant ⚖️ DUA-Governed HIPAA Safe Harbor
0K+
Patient Records
0+
Surgical Specialties
0+
Peer-Reviewed Publications
11,200+
Total Citations
Evidence score
91 / 100
Portfolio performance
Live
Adoption
82%
Market access
68%
Evidence base
91%
Differentiation
74%
h-index
43
De-identified Data OnlyHIPAA Safe Harbor Compliant
IRB-Reviewed ProtocolsInstitutional Ethics Standards
DUA-Governed AccessNational Surgical Registries
Publication-Grade MethodologyLancet · JAMA · Annals of Surgery
Registry Databases
National Registries NIS / HCUP SEER 945K+ Patient Records 11 Surgical Specialties Multi-Registry Validation
Who We Are

Analysis. Consulting. Prediction.

ACP Data Lab is a medical outcomes research firm that bridges academic medicine and biopharmaceutical strategy.

ACP Data Lab specializes in large-scale registry analytics, turning population-level medical data into actionable intelligence for product positioning, market access, and clinical adoption.

Founded by surgeon-scientists with deep expertise in outcomes research, we combine peer-reviewed methodological rigour with a commercial mindset. Our analyses meet the publication standards of journals including The Lancet, Annals of Surgery, and JAMA Surgery — the same credibility now applied to your commercial challenge.

All research uses de-identified registry data accessed under approved Data Use Agreements from the American College of Surgeons, AHRQ, and NCI. No patient-identifiable data is collected or retained. Methodology is documented to regulatory submission standards and available for independent peer review.

A

Analysis

Large-scale registry analytics across 945K+ patient records from national surgical databases — de-identified, IRB-compliant, and DUA-governed.

C

Consulting

Evidence-based strategy for pharmaceutical go-to-market, formulary access, and product differentiation at the medical affairs level.

P

Prediction

Data-driven forecasting for clinical adoption, complication risk stratification, and market access modelling using validated ML approaches.

What We Do

Research-Driven Intelligence.

Every deliverable is grounded in peer-reviewed methodology and designed for commercial impact.

01

Real-World Evidence Development

Large-scale analyses of national surgical registries to generate product-relevant clinical evidence — publishable or white-paper format, designed for regulatory submissions, medical affairs, and payer dossiers.

02

Market Landscape & Opportunity Sizing

Procedure-level quantification of addressable patient populations, prescribing patterns, and treatment pathway analysis. We identify where your product fits in clinical practice and quantify the commercial opportunity.

03

Clinical Adoption Strategy

Hospital-level implementation intelligence: decision-maker mapping, protocol framework development, and P&T Committee evidence packages. From registry data to formulary approval.

For Healthcare Leaders

What Pharmaceutical and Medtech Teams Get From Us.

We answer the specific questions that move products forward — from market access through KOL engagement to formulary approval.

Medical Affairs

Publication-Ready Evidence

Registry analyses that meet top-tier journal standards — credible to payers, KOLs, and regulators because they were built to survive peer review, not just internal review.

Market Access

Payer Dossier Support

Population-level evidence on treatment patterns, complication rates, and outcome differentials — structured for formulary submissions and health technology assessments.

Commercial Strategy

Opportunity Quantification

Procedure-level patient volume, prescribing pattern analysis, and hospital-level segmentation — enabling precise resource allocation and field force targeting.

Platform

Bridge the gap between data and action.

Valuable surgical data exists everywhere — but is rarely shaped into evidence that can be used quickly, credibly, and strategically.

Outcomes analysis — programme overview
Complications
78%
Readmission rate
54%
Length of stay
88%
Prescribing variation
66%
Mortality
42%
7,709Citations
43h-index
Top-tierJournals
Market landscape — opportunity sizing
Cardiothoracic
85%
Orthopaedics
71%
General surgery
93%
Burns & plastics
62%
945K+Records
11+Specialties
NationalCoverage
Decision themes — strategic outputs
Positioning
90%
Adoption mapping
76%
HCP targeting
68%
Forecasting
58%
ReportsExec-ready
SlidesBoard-level
ManuscriptsPub-grade
How We Work

A Formal Engagement Process.

Each engagement follows a structured protocol — from confidential briefing through delivery of a publication-grade analytical package. Fixed-scope pricing, defined milestones, no open-ended retainers.

1
Week 1
Discovery Call
Confidential briefing. We define your commercial challenge and the research question that drives the engagement.
2
Weeks 2–4
Scoping Proposal
Written proposal with registry selection, statistical methodology, deliverable formats, timeline, and fixed-scope pricing.
3
8–16 Weeks
Registry Analysis
Structured analysis with interim read-outs and milestone reporting. Publication-grade statistical methodology throughout.
4
Delivery
Final Package
Final report, slide deck, and supporting data package. Manuscript preparation for peer-reviewed submission available.
Our Approach

We publish the evidence, then translate it.

The methodology behind 300+ peer-reviewed publications and 11,200+ citations — applied to pharmaceutical product strategy, market access, and clinical adoption.

01

Registry Expertise

Deep, firsthand experience with the largest US surgical databases. We know the data architecture, the limitations, and how to extract commercially relevant signals others miss.

02

Publication-Grade Rigour

Our analyses meet the standards of top-tier medical journals. Evidence that withstands scrutiny from Medical Affairs, KOLs, payers, and regulators — because it was built for exactly that scrutiny.

03

Commercial Translation

We translate findings into adoption roadmaps, protocol templates, and field-ready materials. Evidence that moves from registry to formulary to prescription.

Selected Research

Selected Publications.

Representative analyses from our healthcare outcomes research portfolio — each with direct relevance to pharmaceutical strategy and market access.

The Lancet Regional Health — Americas
2026
Post-Surgical Opioid Prescribing in the United States: A National Analysis
N = 945,505 patients · 11 surgical specialties · national registry data
Pharma relevance: Procedure-level opioid exposure data across specialties — directly applicable to pain management product positioning, prescribing pattern segmentation, and market opportunity sizing for analgesics and opioid alternatives.
Annals of Surgery
2025
Variation in Surgical Outcomes Across US Hospital Systems: A Registry-Based Study
Multi-centre analysis of outcome variation and quality benchmarking · NIS database
Pharma relevance: Hospital-level performance stratification enables targeted market access strategies — identifying high-adoption institutions, KOL mapping, and evidence for formulary differentiation arguments.
JAMA Surgery
2024
Predictive Models for Post-Operative Complication Risk: Machine Learning Approaches
Development and validation of ML-based risk stratification tools · Multi-registry validation
Pharma relevance: ML risk models identify high-risk patient subgroups where targeted pharmacologic intervention has the greatest impact — enabling precision market access and outcomes-based contracting arguments.
Leadership

Scientific Leadership.

Surgeon-scientists and research leaders who understand the methodological standards required for serious healthcare evidence.

Dr. Adriana C. Panayi
Adriana C. Panayi, M.D., Ph.D.
Founding Director & Chair of Scientific Leadership
Scientific strategy, study design & pharmaceutical partnership development
7,709
Citations
43
h-index
300+
Publications
Affiliations
Harvard Medical School · Brigham & Women's Hospital · University Hospital Zürich · University College London · University of Cambridge
Prof. Dr. Gabriel Hundeshagen
Prof. Gabriel Hundeshagen, M.M.S., M.D.
Research Associate & Senior Project Manager
Project execution, clinical data analysis & research operations
3,500
Citations
27
h-index
150+
Publications
Affiliations
UTMB Galveston · BG Klinik Ludwigshafen · Heidelberg University
Clinical Role
Managing Senior Consultant, Plastic, Reconstructive & Hand Surgery · Director of Research
Get in Touch

Begin a Confidential Engagement.

We work with pharmaceutical, biotechnology and other medical device companies on a project basis. Every engagement begins with a confidential discovery call — no obligation, no commitment until written scope is agreed.

View Services
Email: [email protected] Response within 48 hours

References and prior engagement scope available upon request under NDA.

🔒
De-identified Data
📋
IRB Compliant
⚖️
DUA Governed
🇪🇺
GDPR Aligned
🏥
HIPAA Safe Harbor
Data Governance & Compliance. All analyses are conducted using de-identified, publicly available research datasets accessed under approved Data Use Agreements (DUAs) from national surgical registries and federal health databases. No patient-identifiable information is collected, used, or stored at any point. Methodology adheres to IRB standards and applicable data governance frameworks including HIPAA Safe Harbor de-identification requirements and GDPR Article 9 derogations for scientific research. Full methodological documentation is available for regulatory and compliance review upon request.

ACP Data Lab Ltd. · [email protected] · All analyses conducted in compliance with applicable data use agreements and research ethics standards.